Research

Schaeffer Center experts propose two different types of payment models applicable to disease-modifying therapies in Alzheimer’s disease, and suggest four strategies to overcome challenges in their implementation.

Examining the frequency and content of messages related to pharmacological and evidence-based, non-pharmaceutical treatments in direct-to-consumer advertising (DTCA) for prescription drugs treating four chronic diseases in the United States.

It is widely recognized that survey satisficing, inattentive, or careless responding in questionnaires reduces the quality of self-report data.

America is facing a behavioral health crisis, both in terms of increasing prevalence rates and high behavioral healthcare needs.

This study explores the impact of multimorbidity and types of chronic diseases on self-rated memory in older adults in the United States.

A National Academies committee will consider the oversight and regulatory processes needed to ensure the public and such workers have access to effective respiratory protective devices and guidance on their use to mitigate exposures to inhalation hazards—including those arising during disasters and public health emergencies.

Schaeffer Initiative experts argue that there is a strong economic case for continued federal investment in COVID-19 vaccines and therapeutics.

Vaccines prevent millions of deaths, and yet millions of people die each year from vaccine-preventable diseases. The primary reason for these deaths is that a significant fraction of the population chooses not to vaccinate. Why don’t people vaccinate, and what can be done to increase vaccination rates besides providing free and easy access to vaccines?

Researchers attempted tp under how COVID-19 affected influenza vaccine utilization and disparities.

Researchers examine the impact of two guidance documents for Alzheimer’s disease (AD) trials. The first guidance in 2013 encouraged the use of cognitive/functional endpoints, while the second in 2018 modified such recommendation.